HER2 Status May Influence Time to Next Treatment Post-Enhertu
Findings were presented at the 2023 San Antonio Breast Cancer Symposium from a study investigating real-world patients who received Enhertu for advanced breast cancer.
Targeted Therapies Shake up the DLBCL Treatment Paradigm, Expert Says
An expert gives an overview of current standard of care and what’s coming down the pipeline in terms of treatment options for diffuse large B-cell lymphoma.
Immunotherapy Agent Misses Study Survival Goal in Advanced Penile Cancer
Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.